Company Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Data adjusted to current consolidation scope
Fiscal Period: December 2025 2026 2027 2028
Market Cap 1 650 4,858 - -
Change - 647.37% - -
Enterprise Value (EV) 1 650 4,778 4,748 4,590
Change - 635.11% -0.63% -3.33%
P/E 5.7x 23.7x 15.8x 12.9x
PBR - 8.35x 6.45x 5.26x
PEG - -0.3x 0.3x 0.6x
Capitalization / Revenue - 4.08x 3.13x 2.5x
EV / Revenue - 4.02x 3.06x 2.36x
EV / EBITDA - 17.6x 12.5x 9.11x
EV / EBIT - 19.9x 14.1x 10.3x
EV / FCF - 101x 26.5x 13.3x
FCF Yield - 0.99% 3.77% 7.54%
Dividend per Share 2 - 0.03 0.04 0.06
Rate of return - 2.11% 2.82% 4.23%
EPS 2 0.2 0.06 0.09 0.11
Distribution rate - 50% 44.4% 54.5%
Net sales 1 - 1,190 1,552 1,946
EBITDA 1 - 271 381 504
EBIT 1 - 240 337 444
Net income 1 115.7 206 283 373
Net Debt 1 - -79.7 -110 -268
Reference price 2 1.140 1.420 1.420 1.420
Nbr of stocks (in thousands) 570,206 3,421,239 - -
Announcement Date 19/02/26 - - -
1EGP in Million2EGP
Estimates

P/E, Detailed evolution



P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
22.5x3.81x16.75x - 85.71M
41.32x13.98x29.71x0.48% 1,258B
41.29x6.93x19.48x1.89% 679B
37.78x8.57x17.7x2.35% 518B
21.56x5.23x13.1x2.5% 390B
105.59x6.02x25.64x2.28% 367B
23.81x5.93x14.32x2.69% 307B
24.64x4.94x13.88x1.76% 293B
24x7.37x13.68x2.17% 252B
-39.75x7.37x46.38x1.95% 210B
Average 30.27x 7.01x 21.06x 2.01% 427B
Weighted average by Cap. 37.19x 8.81x 22.45x 1.69%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Macro Group Pharmaceuticals (Macro Capital) S.A.E

Historical PBR trend

Valuation ratios - PBR - Macro Group Pharmaceuticals (Macro Capital) S.A.E

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Macro Group Pharmaceuticals (Macro Capital) S.A.E

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Macro Group Pharmaceuticals (Macro Capital) S.A.E


Year-on-year evolution of the Yield

Valuation ratios - Yield - Macro Group Pharmaceuticals (Macro Capital) S.A.E
  1. Stock Market
  2. Stocks
  3. MCRO Stock
  4. Valuation Macro Group Pharmaceuticals (Macro Capital) S.A.E